Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease

NCT ID: NCT01491386

Last Updated: 2023-05-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 279 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1998-08-31
• Study Completion Date: 2002-10-31

Brief Summary

This study is designed to assess the safety and effectiveness of the rhBMP-2/ACS/LT-CAGE® device as compared to the LT-CAGE® device with autogenous bone in patients with symptomatic degenerative disc disease using an open surgical technique.

Conditions

Degenerative Disc Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

rhBMP-2/ACS

Group Type: EXPERIMENTAL

rhBMP-2/ACS/LT-CAGE® Device

Intervention Type: DEVICE

LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).

Autogenous Bone

Group Type: ACTIVE_COMPARATOR

Autogenous Bone/LT-CAGE® Device

Intervention Type: DEVICE

LT-CAGE® device with autogenous bone taken from the iliac crest.

Interventions

rhBMP-2/ACS/LT-CAGE® Device

LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).

Intervention Type: DEVICE

Autogenous Bone/LT-CAGE® Device

LT-CAGE® device with autogenous bone taken from the iliac crest.

Intervention Type: DEVICE

Other Intervention Names

Recombinant human bone morphogenetic protein; Autograft

Eligibility Criteria

Inclusion Criteria

1. Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g.,pain [leg, back, or symptoms in the sciatic nerve distribution], function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray, etc.) to include one or more of the following:

• instability (defined as angular motion > 5° and/or translation >= 4mm, based on Flex/Ext radiographs);
• osteophyte formation;
• decreased disc height;
• thickening of ligamentous tissue;
• disc degeneration or herniation; and/or
• facet joint degeneration.

2. Has preoperative Oswestry score > 35.

3. Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW, 1932.).

4. Has single-level symptomatic degenerative involvement from L4 to S1.

5. Is at least 18 years of age, inclusive, at the time of surgery.

6. Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.

7. If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.

8. Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.

Exclusion Criteria

1. Had previous anterior spinal fusion surgical procedure at the involved level.

2. Has posterior spinal instrumentation (which will not be removed) stabilizing the involved level or has had a previous posterior lumbar interbody fusion procedure at the involved level.

3. Has a condition which requires postoperative medications that interfere with fusion, such as steroids.

4. Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.

5. Has presence of active malignancy.

6. Has overt or active bacterial infection, either local or systemic.

7. ls grossly obese, i.e., weight > 40% over ideal for their age and height.

8. Has fever ( temperature > 101° F oral) at the time of surgery.

9. Has a documented titanium alloy allergy or intolerance.

10. Is mentally incompetent. if questionable, obtain psychiatric consult.

11. Has a Waddell Signs of Inorganic Behavior score of 3 or greater.

12. Is a prisoner.

13. Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.

14. Is a tobacco user at the time of surgery.

15. Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).

16. Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).

17. Has a history of exposure to injectable collagen implants.

18. Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.

19. Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.

20. Has received any previous exposure to any/all BMP's of either human or animal extraction.

21. Has a history of allergy to bovine products or a history of anaphylaxis.

22. Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic Spinal and Biologics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

C-9702

Identifier Type: -

Identifier Source: org_study_id